Naproxen (Synonyms: (S)-Naproxen)

Name: Naproxen
Brand: MedChemExpress
SKU: HY-15030
Rating: 5.0 (3 reviews)

Cat. No.: HY-15030 Purity: 99.98%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Naproxen is a COX-1 and COX-2 inhibitor with IC₅₀s of 8.72 and 5.15 μM, respectively in cell assay.

For research use only. We do not sell to patients.

Naproxen Chemical Structure

CAS No. : 22204-53-1

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
5 g	USD 60	In-stock	Estimated Time of Arrival: December 31
10 g	USD 96	In-stock	Estimated Time of Arrival: December 31
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Naproxen:

Naproxen sodium In-stock
(±)-Naproxen Get quote
(rac)-Naproxen-d3 Methyl Ester Get quote
Naproxen-d₃ Get quote
l-Naproxen Get quote
Naproxen (Standard) Get quote

3 Publications Citing Use of MCE Naproxen

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Naproxen is a COX-1 and COX-2 inhibitor with IC₅₀s of 8.72 and 5.15 μM, respectively in cell assay.

IC₅₀ & Target^[1]

COX-2

5.65 μM (IC₅₀)

COX-1

9.55 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	1.4 mM Compound: Naproxen	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30028133]
BGC-823	IC₅₀	> 50 μM Compound: Naproxen	Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
BXPC-3	IC₅₀	2450 μM Compound: 1, NAP	Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
Caco-2	IC₅₀	> 50 μM Compound: Naproxen	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
COS-7	IC₅₀	> 1000 μM Compound: Naproxen	Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
DU-145	IC₅₀	> 100 μM Compound: 3; Nap	Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
Erythrocyte	EC₅₀	756 μM Compound: NPX	Antiinflammatory activity against Wistar rat erythrocytes assessed as inhibition of heat-induced hemolysis after 15 mins by membrane stabilizing activity assay Antiinflammatory activity against Wistar rat erythrocytes assessed as inhibition of heat-induced hemolysis after 15 mins by membrane stabilizing activity assay	[PMID: 25863493]
HCT-15	IC₅₀	> 1000 μM Compound: Naproxen	Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
HT-29	IC₅₀	> 100 μM Compound: 3; Nap	Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
HT-29	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	2600 μM Compound: 1, NAP	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
Jurkat	IC₅₀	2550 μM Compound: 1, NAP	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
K562	IC₅₀	181 μM Compound: Naproxen	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
MCF7	IC₅₀	> 100 μM Compound: 3; Nap	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
MCF7	IC₅₀	> 1000 μM Compound: Naproxen	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
MCF7	IC₅₀	> 400 μM Compound: Naproxen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33743356]
MCF7	IC₅₀	> 50 μM Compound: Naproxen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
MCF7	IC₅₀	2385 μM Compound: 1, NAP	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
MDA-MB-231	IC₅₀	> 400 μM Compound: Naproxen	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33743356]
MDA-MB-231	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
MDCK	CC₅₀	1 mM Compound: Naproxen	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by trypan blue staining based method Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by trypan blue staining based method	[PMID: 30028133]
MDCK	CC₅₀	1.4 mM Compound: Naproxen	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay	[PMID: 30028133]
PANC-1	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
PC-3	IC₅₀	> 1000 μM Compound: Naproxen	Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
PC-3	IC₅₀	> 50 μM Compound: Naproxen	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
SK-LU-1	IC₅₀	> 1000 μM Compound: Naproxen	Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
U-251	IC₅₀	> 1000 μM Compound: Naproxen	Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
UACC-903	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	> 50 μM Compound: Nap	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]

In Vitro

Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a well known nonsteroidal anti-inflammatory drug. Naproxen is approximately equipotent inhibitor of COX-1 and COX-2 in intact cells with IC₅₀s of 2.2 μg/mL and 1.3 μg/mL, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Naproxen exerts an anti-inflammatory and antifibrotic effect in mouse model of bleomycin-induced lung fibrosis. Naproxen also downregulates TGF-β levels and Smad3/4 complex formation^[2]. Naproxen is shown to inhibit the time-courses of pain, fever and PGE2 with similar potencies (IC₅₀=27, 40, 13 μM)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

230.26

Formula

C₁₄H₁₄O₃

CAS No.

22204-53-1

Appearance

Solid

Color

White to off-white

SMILES

C[C@H](C(O)=O)C1=CC2=CC=C(OC)C=C2C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (434.29 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 75 mg/mL (325.72 mM; Need ultrasonic and warming)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.3429 mL	21.7146 mL	43.4292 mL
5 mM	0.8686 mL	4.3429 mL	8.6858 mL
10 mM	0.4343 mL	2.1715 mL	4.3429 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 2 mg/mL (8.69 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (278 KB) SDS (702 KB)

COA (246 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. [Content Brief]

[2]. Rosa AC, et al. Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment. J Pharmacol Exp Ther. 2014 Nov;351(2):308-16. [Content Brief]

[3]. Krekels EH, et al. Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. [Content Brief]

Cell Assay ^[1]	BAEC are incubated for 30 min with Naproxen (0.1 ng/mL to 1 mg/mL). Arachidonic acid (30 μM) is then added, and the cells are incubated for a further 15 min at 37°C. The medium is then removed, and radioimmunoassay is used to measure the formation of 6-keto-PGF,a, PGE2, thromboxane B2, or PGF2a^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]^[3]	Rats^[3] To measure the analgesic effects of naproxen in a carrageenaninduced model of monoarthritis, Male Sprague–Dawley rats (n=48, 217±28 g) are randomly divided into four groups of 12 by an internally developed computer program, allowing the blind performance of the behavioral experiment. To induce hyperalgesia by inflammation, animals in groups 1B, 1C, and 1D receive a 40-μL intra-articular injection of a saline solution containing 7.5 mg/mL carrageenan in the left hind limb under isoflurane anesthesia (time=−1 h). Animals in group 1A receive no injection. After 1 h (time=0) the animals in groups 1A, 1B, 1C, and 1D receive oral doses of naproxen in saline of 0, 0, 7.5 and 30 μmol/kg, respectively. The doses and time points of measurements are selected on the basis of simulations predicting measuring a full concentration-effect relationship within the time-span of the experiment^[3]. Mice^[2] Bleomycin (0.05 IU) is instilled intratracheally to C57BL/6 mice, which are then treated by micro-osmotic pump with vehicle, JNJ7777120 (40 mg/kg b.wt.), naproxen (21 mg/kg b.wt.), or a combination of both. Airway resistance to inflation, an index of lung stiffness, is assessed, and lung specimens are processed for inflammation, oxidative stress, and fibrosis markers^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. [Content Brief] [2]. Rosa AC, et al. Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment. J Pharmacol Exp Ther. 2014 Nov;351(2):308-16. [Content Brief] [3]. Krekels EH, et al. Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	4.3429 mL	21.7146 mL	43.4292 mL	108.5729 mL
	5 mM	0.8686 mL	4.3429 mL	8.6858 mL	21.7146 mL
	10 mM	0.4343 mL	2.1715 mL	4.3429 mL	10.8573 mL
	15 mM	0.2895 mL	1.4476 mL	2.8953 mL	7.2382 mL
	20 mM	0.2171 mL	1.0857 mL	2.1715 mL	5.4286 mL
	25 mM	0.1737 mL	0.8686 mL	1.7372 mL	4.3429 mL
	30 mM	0.1448 mL	0.7238 mL	1.4476 mL	3.6191 mL
	40 mM	0.1086 mL	0.5429 mL	1.0857 mL	2.7143 mL
	50 mM	0.0869 mL	0.4343 mL	0.8686 mL	2.1715 mL
	60 mM	0.0724 mL	0.3619 mL	0.7238 mL	1.8095 mL
	80 mM	0.0543 mL	0.2714 mL	0.5429 mL	1.3572 mL
	100 mM	0.0434 mL	0.2171 mL	0.4343 mL	1.0857 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Naproxen Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Naproxen22204-53-1(S)-NaproxenCOXAutophagyCyclooxygenaseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Naproxen (Synonyms: (S)-Naproxen)

Customer Review

Other Forms of Naproxen:

Naproxen Related Antibodies

3 Publications Citing Use of MCE Naproxen

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Naproxen Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Naproxen Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report